Groupe la Francaise Boosts Holdings in Merck & Co., Inc. $MRK

Groupe la Francaise raised its position in Merck & Co., Inc. (NYSE:MRK) by 56.8% in the 1st quarter, Holdings Channel reports. The firm owned 73,551 shares of the company’s stock after buying an additional 26,631 shares during the quarter. Groupe la Francaise’s holdings in Merck & Co., Inc. were worth $8,840,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Arete Wealth Advisors LLC increased its holdings in shares of Merck & Co., Inc. by 30.8% in the first quarter. Arete Wealth Advisors LLC now owns 51,371 shares of the company’s stock worth $6,179,000 after purchasing an additional 12,096 shares during the period. SOA Wealth Advisors LLC. raised its position in shares of Merck & Co., Inc. by 8.0% in the first quarter. SOA Wealth Advisors LLC. now owns 7,046 shares of the company’s stock worth $848,000 after buying an additional 519 shares in the last quarter. Western Wealth Management LLC boosted its stake in Merck & Co., Inc. by 43.8% during the first quarter. Western Wealth Management LLC now owns 31,978 shares of the company’s stock valued at $3,847,000 after buying an additional 9,739 shares during the period. Eley Financial Management Inc boosted its stake in Merck & Co., Inc. by 1.2% during the first quarter. Eley Financial Management Inc now owns 15,938 shares of the company’s stock valued at $1,917,000 after buying an additional 192 shares during the period. Finally, Orographic Financial Advisors LLC purchased a new position in Merck & Co., Inc. during the first quarter worth about $442,000. 76.07% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on MRK. Cantor Fitzgerald restated a “neutral” rating and issued a $120.00 target price on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Morgan Stanley lifted their price target on Merck & Co., Inc. from $112.00 to $113.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. Scotiabank boosted their price objective on Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a report on Tuesday, June 30th. Guggenheim boosted their price objective on Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Finally, Bank of America upped their price objective on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Thirteen analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and an average target price of $134.50.

Merck & Co., Inc. Stock Down 0.3%

Shares of NYSE:MRK opened at $129.95 on Friday. Merck & Co., Inc. has a 52-week low of $77.53 and a 52-week high of $135.05. The firm has a fifty day moving average of $123.02 and a 200 day moving average of $118.37. The firm has a market capitalization of $320.96 billion, a PE ratio of 36.61, a price-to-earnings-growth ratio of 5.17 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion for the quarter, compared to analysts’ expectations of $15.85 billion. During the same quarter in the prior year, the firm earned $2.22 earnings per share. The firm’s revenue was up 4.9% on a year-over-year basis. As a group, research analysts anticipate that Merck & Co., Inc. will post 2.74 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be issued a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is presently 95.77%.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Barclays raised its price target on Merck from $140 to $150 and maintained an “overweight” rating, implying meaningful potential upside from recent trading levels. Barclays raises Merck price target
• Positive Sentiment: Erste Group modestly increased its fiscal 2027 EPS forecast to $9.54 from $9.52, signaling slightly stronger expectations for Merck’s longer-term earnings power. Erste Group raises Merck EPS estimate
• Positive Sentiment: Merck declared a quarterly dividend of $0.85 per share, payable October 7 to shareholders of record September 15. The dividend supports the stock’s income appeal and represents an annualized yield of approximately 2.7%. Merck announces fourth-quarter dividend
• Positive Sentiment: A Merck-Wellcome joint venture is preparing doses of an experimental Ebola vaccine for clinical trials, providing a potential public-health and pipeline opportunity, although it is not an immediate earnings driver. Merck and Wellcome Ebola vaccine partnership
• Neutral Sentiment: Analysts expect second-quarter revenue of about $16.33 billion and a loss of $0.26 per share, with acquisition-related costs, Keytruda performance, and Gardasil demand likely to determine whether results beat or miss expectations. Merck second-quarter earnings preview
• Neutral Sentiment: Valuation analysis finds Merck attractive on discounted cash flow and cash-flow measures but more fairly valued based on earnings, suggesting further gains will require continued fundamental execution. Merck valuation analysis
• Negative Sentiment: Near-term uncertainty ahead of earnings—including acquisition costs and ongoing Gardasil challenges—may be weighing on sentiment despite expected strength from Keytruda. Merck earnings metrics preview

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.